SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum faces significant downward pressure as investors debate long-term fundamentals against concerns of institutional selling, market manipulation, and lackluster price action. Despite the persistent skepticism and negative sentiment regarding the asset's utility, the community remains actively divided between those calling for a structural bottom and those warning of deeper technical breakdowns.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is currently at the center of intense debate as traders weigh its role in the critical supply chain for indium phosphide wafers against a massive surge in valuation that many observers characterize as a speculative bubble. While some market participants highlight the company's position as a bottleneck provider in the AI infrastructure stack, skeptics point to insider selling and a significant disconnect between current share prices and historical profitability as key risks.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent Biosolutions is trending as investors weigh potential biodefense catalysts, such as new government contracts and Ebola-related news, against concerns over the company's debt structure and operational challenges. The community is actively debating the stock's turnaround potential, with a mix of optimism regarding new pipeline opportunities and skepticism surrounding management's ability to navigate financial hurdles.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors assess the pharmaceutical giant's post-Keytruda strategy, with recent focus on internal organizational restructuring into dedicated units to drive growth. Community discussion remains heavily centered on the competitive landscape of immuno-oncology, particularly comparing Merck's established therapies against emerging candidates in the cancer treatment space.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is experiencing significant market interest driven by robust data from its oncology pipeline and strategic collaborations, including positive developments for Libtayo. Investors are also closely monitoring the company's manufacturing initiatives and ongoing efforts to expand its Eylea franchise, positioning the stock as a focal point for those seeking long-term growth in the biotech sector.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space Inc is experiencing extreme volatility as retail investors debate the company's long-term viability amid concerns over leadership disputes, delayed financial filings, and intense short-selling pressure. While some community members remain optimistic about a potential short squeeze and exposure to the broader space sector growth, others are actively warning of potential dilution and highlighting the company's lack of consistent revenue.

Futu Holdings Ltd. engages in the provision of digitalized financial services. It offers securities brokerage and wealth management products. The company was founded by Leaf Hua Li in December 2007 and is headquartered in Hong Kong.

Futu Holdings Ltd - ADR

Futu Holdings is trending as investors digest the company's latest earnings report and a significant regulatory fine from Chinese authorities regarding its cross-border operations. While the community is actively debating the severity of the enforcement and its long-term impact on the firm's growth outside of mainland China, many remain focused on the potential for an oversold bounce given the company's fundamental performance.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is capturing investor interest as it scales its modular edge data center deployments, driven by rising demand for localized AI compute and its unique ability to provide independent power through mobile assets. The community is actively monitoring the company's backlog growth, expansion into underserved markets, and the potential for strategic partnerships with industry hyperscalers.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors reprice the company's long-term enterprise AI server demand, further fueled by high-profile political endorsements and a blowout revenue report from competitor Lenovo. The community remains focused on the broader AI infrastructure supercycle, actively debating the stock's valuation as analysts continue to raise price targets amid massive backlog growth and strategic on-premise AI deployments.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant momentum and high volume as investors shift focus toward its QNX software as a foundational play for physical AI and industrial robotics. The community is actively celebrating a perceived long-term rerating, with many long-term shareholders viewing this price action as the beginning of a sustained turnaround driven by enterprise fundamentals rather than past meme-stock sentiment.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences PR Newswire WASHINGTON, May 7, 2026...

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -54.72% and -9.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative return on equity of 23.85...

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results PR Newswire WASHINGTON, May 6, 2026 Fanapt net product sales rose...

Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's  What You Should Know

The mean of analysts' price targets for Vanda (VNDA) points to a 105% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a h...

AIGH Capital Management LLC Takes Position in Vanda Pharmaceuticals Inc. $VNDA

AIGH Capital Management LLC purchased a new stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,998,431 shares of the biopharmaceutica...

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug

Equity

The U.S. Food and Drug Administration approved Nereus for the prevention of vomiting induced by motion in adults in December.


Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years Vanda Pharmaceuticals...

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 PR Newswire WASHINGTON...

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

VNDA
Vanda Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest VNDA News

VNDAVanda Pharmaceuticals Inc